# D-0316 First Time in Patients Ascending Dose Study

> **NCT03452150** · PHASE1 · COMPLETED · sponsor: **InventisBio Co., Ltd** · enrollment: 84 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** D-0316

## Key facts

- **NCT ID:** NCT03452150
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-12-31
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452150, "D-0316 First Time in Patients Ascending Dose Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03452150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*